Leukaemia (chronic lymphocytic, first line) - rituximab: review decision - March 2014 information
History
A list of downloadable documents created during development.
Background information
-
-
Appendix B: GE decision paper - March 2014
-
-
Leukaemia (chronic lymphocytic, first line) - rituximab: Review Proposal - January 2014 information
-
Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix A - provisional matrix of stakeholders
-
-
Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix B proposal paper presented to the Institute's Guidance Executive
-
-
Leukaemia (chronic lymphocytic, first line) - rituximab: review update - October 2012 information
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: review update - December 2010 information
-
Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination
-
Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination information
-
Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination
-
Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination (PDF 138 KB)
-
Response to consultee, commentator and public comments on the ACD and comments from website consultation
-
-
Consultee and commentator comments on the ACD
-
Chronic Lymphocytic Leukaemia Support Association
-
Chronic Lymphocytic Leukaemia Support Association (PDF 20 KB)
-
Department of Health
-
-
Leukaemia CARE
-
-
Roche
-
-
Royal College of Nursing
-
-
Royal College of Pathologists
-
-
Comments from website consultation
-
Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation
-
Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation
-
Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation document information
-
Leukaemia (chronic lymphocytic, first line) - rituximab: evaluation report
-
Pre-meeting briefing
-
-
Leukaemia (chronic lymphocytic, first line) - rituximab: evidence review group report
-
Leukaemia (chronic lymphocytic, first line) - rituximab: evidence review group report (PDF 3.61 MB)
-
Non-manufacturer submissions
-
Chronic Lymphocytic Leukaemia Support
-
-
Hampshire PCT
-
-
Royal College of Nursing
-
-
Royal College of Physicians, Medical Oncology Joint Special Committee (on behalf of the NCRI/RCP/RCR/ACP/JCCO)
-
-
UK CLL Forum
-
-
UK CLL Forum, Royal College of Pathologists & British Society for Haematology
-
UK CLL Forum, Royal College of Pathologists & British Society for Haematology (PDF 40 KB)
-
Expert written personal statements
-
Barnard
-
-
Milligan
-
-
Pettitt
-
-
Williams Durkin
-
-
Manufacturer submission
-
Roche submission
-
-
Manufacturer response to clarification letter
-
-
Manufacturer response to supplementary clarification letter
-
Manufacturer response to supplementary clarification letter (PDF 18 KB)
-
NICE clarification letter
-
-
NICE supplementary clarification letter
-
-
Utility Measurement Study for Patients with Chronic Lymphocytic Leukaemia: Interim Report
-
Leukaemia (chronic lymphocytic, first line) - rituximab: final scope (updated following CHMP positive opinion)
-
Leukaemia (chronic lymphocytic, first line) - rituximab: final scope (updated following CHMP positive opinion)
-
Leukaemia (chronic lymphocytic, first line) - rituximab: final scope (PDF 27 KB)
Leukaemia (chronic lymphocytic, first line) - rituximab: final scope
-
Leukaemia (chronic lymphocytic, first line) - rituximab: final scope
-
Leukaemia (chronic lymphocytic, first line) - rituximab: final scope (PDF 27 KB)
Leukaemia (chronic lymphocytic, first line) - rituximab: final matrix of consultees and commentators
-
Leukaemia (chronic lymphocytic, first line) - rituximab: final matrix of consultees and commentators
-
Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the draft scope
-
Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the draft scope
-
Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the draft scope (PDF 74 KB)
Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the provisional matrix
-
Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the provisional matrix
-
Leukaemia (chronic lymphocytic, first line) - rituximab: draft scope
-
Leukaemia (chronic lymphocytic, first line) - rituximab: draft scope
-
Leukaemia (chronic lymphocytic, first line) - rituximab: draft scope (PDF 31 KB)
Leukaemia (chronic lymphocytic, first line) - rituximab: provisional matrix of consultees and commentators
-
Leukaemia (chronic lymphocytic, first line) - rituximab: provisional matrix of consultees and commentators
-